ZD-7288 (ICI-D 7288) is a selective hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker.

ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT1 receptor) antagonist.

ZBMA-1 is a potent HIV-1 replication inhibitor (IC50=1.01 uM) that efficiently protects APOBEC3G protein by targeting Vif-APOBEC3G complex.

Zaurategrast(CDP-323) is an oral α4-integrin inhibitor.

Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester prodrug of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.

Zaurategrast ethyl ester (CDP323), the ethyl ester prodrug of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.

Zatebradine(UL-FS49) is a potent HCN channels antagonist, which decreased the heartbeat in a reversible manner; 92% inhibition of the hHCN1-mediated current at 10 uM.

Zatebradine hydrochloride is a bradycardic agent that creates use-dependent inhibition of hyperpolarization-activated current (If) in sinoatrial node cells (EC50 = 480 nM) and Purkinje fibres.

Zanapezil (TAK-147) is a potent, selective acetylcholinesterase (AChE) inhibitor with IC50 of 97.7 nM.

Zaltoprofen(CN100) is an inhibitor of COX for treatment of arthritis.

Z-590 is a potent inhibitor of macrophage migration inhibitory factor (MIF) tautomerase activity.

Z-505 hydrochloride is a novel, orally active ghrelin (GHSR1a) agonist with EC50 of 2.08 nM and 5.46 nM for rat and mouse GHSR1a, respectively.

YZ129 (YZ-129) is a small molecule inhibitor of HSP90-Calcineurin-NFAT pathway, suppresses TG-induced NFAT nuclear translocation in HeLa cellswith IC50 of 820 nM.

YW3-56 is a potent peptidylarginine deiminase (PAD) inhibitor with inhibitory activity against PAD2 (IC50=0.5-1 uM) and PAD4 (IC50=1-2 uM), inhibits U2OS cancer cell growth with IC50 of 2.5 uM.

YU142670 is a highly specific, soluble OCRL/INPP5B inhibitor that directly interacts with the catalytic domain of INPP5B.

YPC-22026, a metabolically stable derivative of YPC-21661, is a novel small molecule inhibitor of the transcription factor Zinc-finger protein 143 (ZNF143), inhibits the binding of ZNF143 to DNA.

YPC-21661 is a novel small molecule inhibitor of the transcription factor Zinc-finger protein 143 (ZNF143).

Yohimbine is an indole alkaloid that has high affinity for the α2-adrenergic receptors with Ki of 1 nM for α2A, α2B and α2C.

YM116 is a potent CYP17A1 (17,20-lyase) inhibitor with IC50 with Ki of 0.38 nM, inhibits C17-20 lyase activity in human testicular microsomes with IC50 of 4.2 nM.

YM 254890 is a selective Gq signaling inhibitor that strongly inhibits intracellular calcium ion mobilization and serum response element (SRE)-mediated transcription stimulated by several receptors coupled to Gq, but not those coupled to Gi, Gs, or G15.

YLC2-155 is a novel potent HIV-1 reverse transcriptase (RT) inhibitor that inhibits both polymerase (IC50=2.6 uM) and RNase H function (IC50=0.65 uM) of RT.

YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

YKL-1-116 is a potent, selective and covalent inhibitor of CDK7 that does not inhibit other CDKs.

YK5 is a small molecule inhibitor of Hsp70 and Hsc70, induces the degradation of HER2, Raf-1, and Akt kinases, also induces apoptosis in the SKBr3 breast cancer cells..

YIR-821 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.8 uM against YTA48P virus with no significant cytotoxicity (CC50>200 uM).

YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM).

YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM).

YIL-781 Ghrelin receptor antagonist (GHS-R1a) (Ki = 17 nM).

YHO-13351 is an orally available prodrug of YHO-13177, which can specifically reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.

YHO-13351 is an orally available prodrug of YHO-13177, which can specifically reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.